Methods and kits for the diagnosis of cancer
AssigneesBioNTech Disgnostics GmbH, TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gemeinnützige GmbH
InventorsRainer Hipfel, Clara Werner, Andree Rothermel, Ugur Sahin, Yvonne Kuhne
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods and kits for the diagnosis, prognosis and/or monitoring of cancer in a patient. The present invention further relates to isolated peptides, panels of isolated peptides and diagnostic devices.
Claims26
A method for the diagnosis, prognosis and/or monitoring of and treating lung cancer in a patient, the method comprising detecting and/or determining the amount of autoantibodies in a biological sample isolated from the patient that specifically bind isolated peptides on a panel, wherein the panel of isolated peptides comprises at least one isolated peptide for each of SEQ ID NOs:
- 1 to 21, wherein the isolated peptides consist of 12 to 25 amino acid residues and comprise at least 12 contiguous amino acids for each of SEQ ID NOs:
- 1 to 21;
- and treating the lung cancer in the patient, wherein the treatment comprises administering surgery, chemotherapy, hormonal therapy, radiation therapy, or immunotherapy/targeted therapy to the patient.
A method of detecting and/or determining the amount of autoantibodies specifically binding to a panel of isolated peptides in a biological sample isolated from a patient and treating the patient, the method comprising:
- obtaining a biological sample from a patient and detecting and/or determining the amount of autoantibodies that specifically bind isolated peptides on the panel by contacting the biological sample with the isolated peptides on the panel, wherein the panel of isolated peptides comprises at least one isolated peptide for each of SEQ ID NOs:
- 1 to 21, wherein the isolated peptides consist of 12 to 25 amino acid residues and comprise at least 12 contiguous amino acid residues for each of SEQ ID NOs:
- 1 to 21 and detecting and/or determining the amount of autoantibodies specifically binding to the panel of isolated peptides;
- and treating the patient, wherein the treatment comprises administering surgery, chemotherapy, hormonal therapy, radiation therapy, or immunotherapy/targeted therapy to the patient.
Dependencies are inferred from the claim text.